Bekir Doğan
Research Subjects
Bekir Doğan has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Mesut Yilmaz
Department of Medical Oncology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul 34147, Türkiye
4 shared publications - Ali Kaan Güren
Marmara Üniversitesi
2 shared publications - Ayberk Bayramgil
Department of Internal Medicine, Istanbul Medipol University, Istanbul 34000, Turkey
2 shared publications - Deniz Tural
Department of Medical Oncology, Koç University School of Medicine, Istanbul, Turkey
2 shared publications - Emir Celik
Department of Medical Oncology, Faculty of Medicine, Topkapi Liv Hospital, Istinye University, Istanbul 34010, Türkiye
2 shared publications - İlKer Nihat Okten
Department of Medical Oncology, Istanbul Medeniyet University, Göztepe Şehir Hospital, 34722 Istanbul, Türkiye
2 shared publications
Latest Publications
- 8 October 2026
- Published by SAGE Publications in Tumori Journal
Prognostic value of CT-measured baseline tumor volume in nivolumab-treated metastatic renal cell carcinoma
Objective: To evaluate the association between baseline metastatic tumor volume measured on computed tomography (CT) and survival outcomes in patients with metastatic renal cell carcinoma (mRCC) receiving nivolumab as second line or later line therapy. Materials and Methods: We retrospectively analyzed 43 patients with mRCC treated with nivolumab between August 2013 and March 2022. Baseline metastatic tumor volume was measured on CT scans obtained within 30 days before treatment initiation. The cohort median (117 cm 3 ) was used as an exploratory, data derived cut-off to define low- and high-volume groups. Progression free survival (PFS) and overall survival (OS) were evaluated using Kaplan–Meier analysis and Cox proportional hazards models. Results: Median PFS and OS were 26.97 and 28.11 months, respectively. Median PFS was 40.62 months in the low-volume group and 9.74 months in the high-volume group (p=0.012), while median OS was 46.9 and 12.89 months, respectively (p=0.006). High tumor volume and multiple metastatic sites were associated with poorer survival outcomes. Baseline imbalances in IMDC risk classification and nivolumab treatment line were observed between groups. Conclusion: Higher baseline metastatic tumor volume was associated with poorer survival outcomes in patients with mRCC treated with nivolumab. CT-based tumor volumetry may provide complementary prognostic information; however, these exploratory findings require validation in larger, prospective cohorts.
- 8 October 2026
- Published by SAGE Publications in Tumori Journal
Prognostic value of CT-measured baseline tumor volume in nivolumab-treated metastatic renal cell carcinoma
Objective: To evaluate the association between baseline metastatic tumor volume measured on computed tomography (CT) and survival outcomes in patients with metastatic renal cell carcinoma (mRCC) receiving nivolumab as second line or later line therapy. Materials and Methods: We retrospectively analyzed 43 patients with mRCC treated with nivolumab between August 2013 and March 2022. Baseline metastatic tumor volume was measured on CT scans obtained within 30 days before treatment initiation. The cohort median (117 cm 3 ) was used as an exploratory, data derived cut-off to define low- and high-volume groups. Progression free survival (PFS) and overall survival (OS) were evaluated using Kaplan–Meier analysis and Cox proportional hazards models. Results: Median PFS and OS were 26.97 and 28.11 months, respectively. Median PFS was 40.62 months in the low-volume group and 9.74 months in the high-volume group (p=0.012), while median OS was 46.9 and 12.89 months, respectively (p=0.006). High tumor volume and multiple metastatic sites were associated with poorer survival outcomes. Baseline imbalances in IMDC risk classification and nivolumab treatment line were observed between groups. Conclusion: Higher baseline metastatic tumor volume was associated with poorer survival outcomes in patients with mRCC treated with nivolumab. CT-based tumor volumetry may provide complementary prognostic information; however, these exploratory findings require validation in larger, prospective cohorts.
- Open Access
Erythrocyte Transfusion as an Independent Predictor of Survival but Not Immune-Related Toxicity in Nivolumab-Treated Metastatic NSCLC: A Multicenter Cohort
Background and Objectives: Transfusion-related immunomodulation (TRIM) is a recognized immunosuppressive phenomenon whose interaction with immune checkpoint blockade remains poorly defined. We evaluated the impact of erythrocyte suspension transfusion on survival and immune-related toxicity in patients with metastatic non-small cell lung cancer (NSCLC) treated with nivolumab. Materials and Methods: This retrospective, multicenter study included 253 patients with metastatic NSCLC treated with nivolumab across five centers between April 2018 and March 2025. Patients who received a transfusion within three months before or during nivolumab therapy were compared with non-transfused patients. Survival was assessed using Kaplan–Meier and Cox regression analyses. Results: Forty-two patients (16.6%) received transfusion. Transfused patients had significantly shorter progression-free survival (PFS) (median 3.6 vs. 9.3 months; HR = 2.28, 95% CI 1.47–3.56, p < 0.001) and overall survival (OS) (median 5.8 vs. 16.3 months; HR = 2.76, 95% CI 1.86–4.11, p < 0.001). In multivariable analysis, transfusion was an independent predictor of both shorter PFS (HR = 2.288, 95% CI 1.470–3.561, p < 0.001) and shorter OS (HR = 2.351, 95% CI 1.565–3.533, p < 0.001), independent of transfusion volume. No statistically significant association was detected between transfusion status and the incidence of nivolumab-related toxicity (p = 0.585), although this analysis was likely underpowered, whereas nivolumab-related toxicity was an independent favorable prognostic factor. Conclusions: Erythrocyte transfusion independently predicted poorer survival but not immune-related toxicity in nivolumab-treated metastatic NSCLC, supporting more judicious transfusion practices during immunotherapy.
Open AccessErythrocyte Transfusion as an Independent Predictor of Survival but Not Immune-Related Toxicity in Nivolumab-Treated Metastatic NSCLC: A Multicenter Cohort
Background and Objectives: Transfusion-related immunomodulation (TRIM) is a recognized immunosuppressive phenomenon whose interaction with immune checkpoint blockade remains poorly defined. We evaluated the impact of erythrocyte suspension transfusion on survival and immune-related toxicity in patients with metastatic non-small cell lung cancer (NSCLC) treated with nivolumab. Materials and Methods: This retrospective, multicenter study included 253 patients with metastatic NSCLC treated with nivolumab across five centers between April 2018 and March 2025. Patients who received a transfusion within three months before or during nivolumab therapy were compared with non-transfused patients. Survival was assessed using Kaplan–Meier and Cox regression analyses. Results: Forty-two patients (16.6%) received transfusion. Transfused patients had significantly shorter progression-free survival (PFS) (median 3.6 vs. 9.3 months; HR = 2.28, 95% CI 1.47–3.56, p < 0.001) and overall survival (OS) (median 5.8 vs. 16.3 months; HR = 2.76, 95% CI 1.86–4.11, p < 0.001). In multivariable analysis, transfusion was an independent predictor of both shorter PFS (HR = 2.288, 95% CI 1.470–3.561, p < 0.001) and shorter OS (HR = 2.351, 95% CI 1.565–3.533, p < 0.001), independent of transfusion volume. No statistically significant association was detected between transfusion status and the incidence of nivolumab-related toxicity (p = 0.585), although this analysis was likely underpowered, whereas nivolumab-related toxicity was an independent favorable prognostic factor. Conclusions: Erythrocyte transfusion independently predicted poorer survival but not immune-related toxicity in nivolumab-treated metastatic NSCLC, supporting more judicious transfusion practices during immunotherapy.
- Open Access
- 8 August 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (8) , 472
Revisiting Platinum Sensitivity in Relapsed Small-Cell Lung Cancer: Outcomes of Platinum-Containing Doublet Chemotherapy in the 3–6 Month Relapse Window
Background: Second-line treatment selection in relapsed extensive-stage small-cell lung cancer (ES-SCLC) is commonly guided by the platinum-free interval, but the optimal approach for patients progressing 3–6 months after first-line platinum-based therapy remains uncertain. We compared platinum-containing doublet chemotherapy with single-agent chemotherapy in this clinically ambiguous subgroup. Methods: This multicenter retrospective real-world cohort study included patients with ES-SCLC or recurrent metastatic SCLC after prior limited-stage disease who received first-line platinum-based chemotherapy, achieved disease control, and progressed within a platinum-free interval of 90–180 days. Treatment allocation was at the discretion of the treating physician and was not randomized. The primary endpoint was progression-free survival (PFS); secondary endpoints were overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety. Because of the non-randomized design, the treatment effect was examined across multiple analytic approaches, including multivariable Cox regression, propensity score adjustment, and stabilized inverse probability of treatment weighting (IPTW). Results: Of 105 patients, 54 received single-agent chemotherapy and 51 received platinum-containing doublet therapy; 39 (37.1%) had received first-line atezolizumab. Baseline characteristics were imbalanced in favor of the doublet group, which had a longer platinum-free interval, fewer pleural metastases, and a higher rate of objective response to first-line therapy. ORR was higher with doublet therapy (31.4% vs. 11.1%, p = 0.016), as was DCR (62.7% vs. 33.3%, p = 0.003). Median PFS was 4.4 months (95% CI 3.4–5.8) with doublet therapy versus 3.1 months (95% CI 2.7–3.7) with single-agent chemotherapy (unadjusted HR 0.53, 95% CI 0.36–0.80; p = 0.002). Median OS was 6.5 months (95% CI 5.4–8.0) versus 5.4 months (95% CI 4.1–6.0), a difference that was not statistically significant (HR 0.68, 95% CI 0.46–1.01; p = 0.054). The PFS estimate favored doublet therapy in all sensitivity analyses but was attenuated with increasingly complete adjustment for treatment selection (multivariable HR 0.46, 95% CI 0.29–0.72; propensity-adjusted HR 0.58, 95% CI 0.38–0.88; IPTW HR 0.68, 95% CI 0.38–1.20, p = 0.184). No OS estimate reached statistical significance in any model. Grade ≥ 3 adverse events were similar between groups (66.7% vs. 64.8%, p = 0.842). Conclusions: In this non-randomized cohort of patients relapsing within a 90–180-day platinum-free interval, platinum-containing doublet chemotherapy was associated with higher response rates and longer PFS, without an increase in severe toxicity, but no overall survival benefit was demonstrated. Because baseline prognostic factors consistently favored the doublet group and the PFS advantage was attenuated after propensity-based adjustment, these findings should be regarded as hypothesis-generating. They are nonetheless consistent with randomized data showing improved PFS but not OS with platinum rechallenge, and support platinum-containing rechallenge as a reasonable option in carefully selected patients rather than as a demonstrated survival-prolonging strategy.
- 8 August 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (8) , 472
Open AccessRevisiting Platinum Sensitivity in Relapsed Small-Cell Lung Cancer: Outcomes of Platinum-Containing Doublet Chemotherapy in the 3–6 Month Relapse Window
Background: Second-line treatment selection in relapsed extensive-stage small-cell lung cancer (ES-SCLC) is commonly guided by the platinum-free interval, but the optimal approach for patients progressing 3–6 months after first-line platinum-based therapy remains uncertain. We compared platinum-containing doublet chemotherapy with single-agent chemotherapy in this clinically ambiguous subgroup. Methods: This multicenter retrospective real-world cohort study included patients with ES-SCLC or recurrent metastatic SCLC after prior limited-stage disease who received first-line platinum-based chemotherapy, achieved disease control, and progressed within a platinum-free interval of 90–180 days. Treatment allocation was at the discretion of the treating physician and was not randomized. The primary endpoint was progression-free survival (PFS); secondary endpoints were overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety. Because of the non-randomized design, the treatment effect was examined across multiple analytic approaches, including multivariable Cox regression, propensity score adjustment, and stabilized inverse probability of treatment weighting (IPTW). Results: Of 105 patients, 54 received single-agent chemotherapy and 51 received platinum-containing doublet therapy; 39 (37.1%) had received first-line atezolizumab. Baseline characteristics were imbalanced in favor of the doublet group, which had a longer platinum-free interval, fewer pleural metastases, and a higher rate of objective response to first-line therapy. ORR was higher with doublet therapy (31.4% vs. 11.1%, p = 0.016), as was DCR (62.7% vs. 33.3%, p = 0.003). Median PFS was 4.4 months (95% CI 3.4–5.8) with doublet therapy versus 3.1 months (95% CI 2.7–3.7) with single-agent chemotherapy (unadjusted HR 0.53, 95% CI 0.36–0.80; p = 0.002). Median OS was 6.5 months (95% CI 5.4–8.0) versus 5.4 months (95% CI 4.1–6.0), a difference that was not statistically significant (HR 0.68, 95% CI 0.46–1.01; p = 0.054). The PFS estimate favored doublet therapy in all sensitivity analyses but was attenuated with increasingly complete adjustment for treatment selection (multivariable HR 0.46, 95% CI 0.29–0.72; propensity-adjusted HR 0.58, 95% CI 0.38–0.88; IPTW HR 0.68, 95% CI 0.38–1.20, p = 0.184). No OS estimate reached statistical significance in any model. Grade ≥ 3 adverse events were similar between groups (66.7% vs. 64.8%, p = 0.842). Conclusions: In this non-randomized cohort of patients relapsing within a 90–180-day platinum-free interval, platinum-containing doublet chemotherapy was associated with higher response rates and longer PFS, without an increase in severe toxicity, but no overall survival benefit was demonstrated. Because baseline prognostic factors consistently favored the doublet group and the PFS advantage was attenuated after propensity-based adjustment, these findings should be regarded as hypothesis-generating. They are nonetheless consistent with randomized data showing improved PFS but not OS with platinum rechallenge, and support platinum-containing rechallenge as a reasonable option in carefully selected patients rather than as a demonstrated survival-prolonging strategy.
- Open Access
- 17 June 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (6) , 365
Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study
Germline BRCA1/2-mutated (gBRCAm) hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) is a biologically distinct subset in which the efficacy of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors remains incompletely characterized. We evaluated real-world outcomes and prognostic factors in a multicenter retrospective Turkish cohort treated with a CDK4/6 inhibitor plus endocrine therapy (June 2020–September 2025). Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan–Meier and Cox methods. Among 121 patients, 30 (24.8%) had BRCA1, 88 (72.7%) had BRCA2, and three (2.5%) had dual mutations; 66.9% received first-line therapy, with ribociclib in 69.4% and palbociclib in 29.8%. Objective response rate was 69.4% and the clinical benefit rate was 82.6%. Median PFS was 17.0 months and OS 47.0 months. PFS was numerically longer in BRCA1 than in BRCA2 carriers (25.0 vs. 14.0 months), although the difference was not statistically significant in the pairwise comparison (HR 1.50, 95% CI 0.88–2.56; log-rank p = 0.135); the dual BRCA1/2 subgroup (n = 3) had the poorest outcomes and was assessed descriptively. OS did not differ significantly between BRCA1 and BRCA2 carriers (57.0 vs. 49.0 months; log-rank p = 0.520). PFS did not differ between ribociclib and palbociclib (p = 0.192); OS favored ribociclib at borderline significance (p = 0.050), but this was not confirmed in Cox regression. In multivariable analysis, ECOG ≥ 1 (HR 1.85; p = 0.010) and fulvestrant-based therapy (HR 1.74; p = 0.041) predicted shorter PFS; fulvestrant also predicted worse OS (HR 2.39; p = 0.008). CDK4/6 inhibitor-based therapy shows meaningful activity in gBRCAm HR+/HER2- MBC; the numerically poorer outcomes observed in BRCA2 carriers are hypothesis-generating and warrant validation in larger cohorts.
- 17 June 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (6) , 365
Open AccessReal-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study
Germline BRCA1/2-mutated (gBRCAm) hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) is a biologically distinct subset in which the efficacy of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors remains incompletely characterized. We evaluated real-world outcomes and prognostic factors in a multicenter retrospective Turkish cohort treated with a CDK4/6 inhibitor plus endocrine therapy (June 2020–September 2025). Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan–Meier and Cox methods. Among 121 patients, 30 (24.8%) had BRCA1, 88 (72.7%) had BRCA2, and three (2.5%) had dual mutations; 66.9% received first-line therapy, with ribociclib in 69.4% and palbociclib in 29.8%. Objective response rate was 69.4% and the clinical benefit rate was 82.6%. Median PFS was 17.0 months and OS 47.0 months. PFS was numerically longer in BRCA1 than in BRCA2 carriers (25.0 vs. 14.0 months), although the difference was not statistically significant in the pairwise comparison (HR 1.50, 95% CI 0.88–2.56; log-rank p = 0.135); the dual BRCA1/2 subgroup (n = 3) had the poorest outcomes and was assessed descriptively. OS did not differ significantly between BRCA1 and BRCA2 carriers (57.0 vs. 49.0 months; log-rank p = 0.520). PFS did not differ between ribociclib and palbociclib (p = 0.192); OS favored ribociclib at borderline significance (p = 0.050), but this was not confirmed in Cox regression. In multivariable analysis, ECOG ≥ 1 (HR 1.85; p = 0.010) and fulvestrant-based therapy (HR 1.74; p = 0.041) predicted shorter PFS; fulvestrant also predicted worse OS (HR 2.39; p = 0.008). CDK4/6 inhibitor-based therapy shows meaningful activity in gBRCAm HR+/HER2- MBC; the numerically poorer outcomes observed in BRCA2 carriers are hypothesis-generating and warrant validation in larger cohorts.
- Open Access
- 8 May 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (19) , e48711
Prognostic factors and survival outcomes in older adults with extensive-stage small cell lung cancer: A multicenter retrospective cohort study
Extensive-stage small cell lung cancer (ES-SCLC) in older adults is associated with poor outcomes, and optimal management in this population remains challenging. This study aimed to identify clinical and treatment-related factors associated with survival in patients aged ≥70 years with ES-SCLC. A retrospective multicenter cohort study included 135 older adults (aged ≥70 years) diagnosed with ES-SCLC across 3 tertiary centers. All patients received at least 1 cycle of platinum–etoposide–based chemotherapy. Demographic, clinical, and treatment variables – including metastatic sites, number of chemotherapy cycles, thoracic radiotherapy (TRT), prophylactic cranial irradiation, and palliative radiotherapy to extracranial metastases – were collected. Survival outcomes were estimated using the Kaplan–Meier method and compared using the log-rank test. Prognostic factors for progression-free survival and overall survival (OS) were evaluated using Cox proportional hazards regression models. The median age was 73.2 years; 88.1% of patients were male. The objective response rate was 69.9%. Median progression-free survival and OS were 7.1 and 8.3 months, respectively (95% CI: 6.09–8.17 and 7.67–8.93). In multivariate analysis, Eastern Cooperative Oncology Group performance status ≥2 ( P <.001), liver metastases ( P = .006), fewer than 4 chemotherapy cycles ( P <.001), absence of prophylactic cranial irradiation ( P = .028), and lack of palliative radiotherapy to extracranial metastases ( P <.001) were independently associated with shorter OS. TRT did not retain statistical significance in multivariate analysis. Only 34.1% of patients received second-line therapy. The 1-year and 2-year OS rates were 33% and 12%, respectively. Fit older adults (Eastern Cooperative Oncology Group performance status 0–1) may derive meaningful survival benefit from multimodal treatment strategies. Treatment decisions should be individualized based on functional status rather than chronological age alone. Prospective studies incorporating comprehensive geriatric assessment are warranted.
- 8 May 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (19) , e48711
Open AccessPrognostic factors and survival outcomes in older adults with extensive-stage small cell lung cancer: A multicenter retrospective cohort study
Extensive-stage small cell lung cancer (ES-SCLC) in older adults is associated with poor outcomes, and optimal management in this population remains challenging. This study aimed to identify clinical and treatment-related factors associated with survival in patients aged ≥70 years with ES-SCLC. A retrospective multicenter cohort study included 135 older adults (aged ≥70 years) diagnosed with ES-SCLC across 3 tertiary centers. All patients received at least 1 cycle of platinum–etoposide–based chemotherapy. Demographic, clinical, and treatment variables – including metastatic sites, number of chemotherapy cycles, thoracic radiotherapy (TRT), prophylactic cranial irradiation, and palliative radiotherapy to extracranial metastases – were collected. Survival outcomes were estimated using the Kaplan–Meier method and compared using the log-rank test. Prognostic factors for progression-free survival and overall survival (OS) were evaluated using Cox proportional hazards regression models. The median age was 73.2 years; 88.1% of patients were male. The objective response rate was 69.9%. Median progression-free survival and OS were 7.1 and 8.3 months, respectively (95% CI: 6.09–8.17 and 7.67–8.93). In multivariate analysis, Eastern Cooperative Oncology Group performance status ≥2 ( P <.001), liver metastases ( P = .006), fewer than 4 chemotherapy cycles ( P <.001), absence of prophylactic cranial irradiation ( P = .028), and lack of palliative radiotherapy to extracranial metastases ( P <.001) were independently associated with shorter OS. TRT did not retain statistical significance in multivariate analysis. Only 34.1% of patients received second-line therapy. The 1-year and 2-year OS rates were 33% and 12%, respectively. Fit older adults (Eastern Cooperative Oncology Group performance status 0–1) may derive meaningful survival benefit from multimodal treatment strategies. Treatment decisions should be individualized based on functional status rather than chronological age alone. Prospective studies incorporating comprehensive geriatric assessment are warranted.